Alpha Tau Medical Ltd. current report, Q4 FY2022

Business Context and Reporting Period

Alpha Tau Medical Ltd. furnished this Form 6-K for November 2022. On November 2, 2022, the company held its annual general meeting of shareholders at its headquarters in Jerusalem, Israel.

Financial and Operating Metrics

This filing does not provide financial statements, revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.

Material Changes and Corporate Actions

  • Shareholders re-elected Alan Adler and S. Morry Blumenfeld as Class I directors. Their terms run until the close of the 2025 annual general meeting, subject to earlier vacancy or successor appointment under applicable law and the company’s governing documents.
  • Shareholders approved the re-appointment of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as the company’s independent registered public accounting firm for the year ending December 31, 2022 and through the next annual general meeting.
  • The board, with authority to delegate to its audit committee, was authorized to determine the auditors’ fees.
  • All proposals were approved by the required majorities under Israeli law and the company’s Articles of Association.
  • The filing was incorporated by reference into the company’s Form S-8 registration statement, File No. 333-264169.

Guidance, Outlook, Risks, and Unusual Items

The filing does not provide financial guidance, an operating outlook, management commentary, new risk disclosures, contingencies, or unusual financial items. Its disclosures are limited to annual meeting results and related corporate governance matters.

Investor Verification Items

  • Verify the director terms, independence, and committee assignments in subsequent filings and the company’s governance disclosures.
  • Verify the independent auditor’s appointment and audit fees in the company’s 2022 annual report on Form 20-F.
  • Review subsequent filings for financial results, financing activity, cash runway, clinical developments, and changes in risk factors, none of which are addressed in this Form 6-K.